Announcements Trials
Browse Landscape

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 79Observational 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Cardiovascular Diseases 1

Interventions

Surveys and Questionnaires 529Blood Specimen Collection 406Surgical Procedures, Operative 152Radiotherapy 131Interviews as Topic 131Drug Therapy 123Observation 122Magnetic Resonance Spectroscopy 104Biopsy 103Specimen Handling 70Data Collection 70Neoadjuvant Therapy 65Immunohistochemistry 64Magnetic Resonance Imaging 61Immune Checkpoint Inhibitors 59Watchful Waiting 52Immunotherapy 51Bevacizumab 50Positron Emission Tomography Computed Tomography 46Ultrasonography 44Hematologic Tests 42Liquid Biopsy 41Tomography, X-Ray Computed 40Therapeutics 40Radiosurgery 40Colonoscopy 40pembrolizumab 37Hepatectomy 37Gene Expression Profiling 36High-Energy Shock Waves 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Observational × zanubrutinib × Clear all
NCT06441214 2026-01-05

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Fondazione Italiana Linfomi - ETS

Active not recruiting
212 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT07283965 2025-12-16

Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

University Hospital, Caen

Not yet recruiting
15,000 enrolled

Cardiovascular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡